💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?

A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.

Join the conversation on enhancing vaccination strategies for better health outcomes!

#SyenzaNews #Healthcare #HealthEconomics

💡 Are biosimilars the key to transforming U.S. healthcare costs?

A recent study reveals that as more biosimilars enter the market, original product prices drop significantly—by as much as 10-13% per competitor! This shift has led to astonishing savings, totaling $23.6 billion for Medicare between 2015 and 2023. However, concerns linger about the long-term sustainability of this competitive pricing environment.

Dive into the insights on how this booming market balances immediate cost reductions with potential future challenges.

#SyenzaNews #HealthEconomics #Pharmaceuticals #HealthcarePolicy

💡 Are U.S. and global drug prices set for a revolution?

The new Most-Favored-Nation (MFN) drug pricing policy from the HHS and CMS aims to align U.S. pharmaceutical prices with those in economically comparable countries, promising significant reductions without stifling innovation. This bold move could lead to more accessible medications for Americans while reshaping global pricing strategies.

Curious about how this might impact your commercial and pricing strategy? Dive into the details!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation #DrugPricing